Scholarlink

Background <p>Acral lentiginous melanoma (ALM) has a worse prognosis than non-ALM subtypes and poorly understood genetic profile, limiting therapy options. This study compares outcomes of isolated limb infusion or perfusion (ILI/ILP) in patients with ALM or non-ALM.</p> Methods <p>A multi-institution retrospective review including patients with unresectable melanoma in-transit metastases (ITM) treated with ILI/ILP from 2002 to 2023.</p> Results <p>A total of 364 patients were identified: 55% female; median age 71 years; 84 with ALM; 280 non-ALM. Acral lentiginous melanoma tumors had deeper Breslow thickness (4 mm vs. 2.9 mm, <i>P</i> = .005) and more frequent ulceration (38% vs. 27%, <i>P</i> = .03). On multivariable analysis, there were no differences in complete or overall response rates between ALM vs. non-ALM. Median follow-up was 3 years. On Kaplan-Meier analysis, median progression-free survival (PFS) was shorter for ALM (5.6 vs. 7.7 months, <i>P</i> = .02). Out-of-field PFS was shorter for ALM (9.6 vs. 15.3 months, <i>P</i> = .02). Disease-specific survival was shorter for ALM (3.5 vs. 7.8 years, <i>P</i> = .008). In-field PFS and overall survival were not different for ALM vs. non-ALM. On multivariable analysis, there were no differences in PFS (hazard ratio [HR] 1.32, 95% confidence interval [CI] 1.0–1.74; <i>P</i> = .05) or in-field PFS (HR 1.25, 95% CI 0.95–1.65; <i>P</i> = .1). Out-of-field PFS remained shorter for ALM (HR 1.44, 95% CI 1.09–1.91; <i>P</i> = .01).</p> Conclusions <p>Isolated limb infusion or perfusion is equally effective in achieving locoregional disease control in patients with ALM or non-ALM ITM. Disease-specific survival and out-of-field PFS were significantly shorter with ALM, likely reflective of ALM’s more aggressive biology, and highlights a potential opportunity for systemic therapy with ILI/ILP to optimize local and distant disease control.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Isolated Limb Infusion/Perfusion for Unresectable Acral Versus Non-Acral Melanoma In-Transit Metastases

  • 期刊论文

  • 发表日期：

    2025年5月24日

查看全文
  • Michelle M. Dugan,
  • Jacob Israeli,
  • Nicholas Chin,
  • Caitlyn Balsay-Patel,
  • Anne Huibers,
  • Wenyi Fan,
  • Roger Olofsson Bagge,
  • Jonathan S. Zager

摘要

Background

Acral lentiginous melanoma (ALM) has a worse prognosis than non-ALM subtypes and poorly understood genetic profile, limiting therapy options. This study compares outcomes of isolated limb infusion or perfusion (ILI/ILP) in patients with ALM or non-ALM.

Methods

A multi-institution retrospective review including patients with unresectable melanoma in-transit metastases (ITM) treated with ILI/ILP from 2002 to 2023.

Results

A total of 364 patients were identified: 55% female; median age 71 years; 84 with ALM; 280 non-ALM. Acral lentiginous melanoma tumors had deeper Breslow thickness (4 mm vs. 2.9 mm, P = .005) and more frequent ulceration (38% vs. 27%, P = .03). On multivariable analysis, there were no differences in complete or overall response rates between ALM vs. non-ALM. Median follow-up was 3 years. On Kaplan-Meier analysis, median progression-free survival (PFS) was shorter for ALM (5.6 vs. 7.7 months, P = .02). Out-of-field PFS was shorter for ALM (9.6 vs. 15.3 months, P = .02). Disease-specific survival was shorter for ALM (3.5 vs. 7.8 years, P = .008). In-field PFS and overall survival were not different for ALM vs. non-ALM. On multivariable analysis, there were no differences in PFS (hazard ratio [HR] 1.32, 95% confidence interval [CI] 1.0–1.74; P = .05) or in-field PFS (HR 1.25, 95% CI 0.95–1.65; P = .1). Out-of-field PFS remained shorter for ALM (HR 1.44, 95% CI 1.09–1.91; P = .01).

Conclusions

Isolated limb infusion or perfusion is equally effective in achieving locoregional disease control in patients with ALM or non-ALM ITM. Disease-specific survival and out-of-field PFS were significantly shorter with ALM, likely reflective of ALM’s more aggressive biology, and highlights a potential opportunity for systemic therapy with ILI/ILP to optimize local and distant disease control.